Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT02731118 |
| Other study ID # |
Sal/2016 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
April 2016 |
| Est. completion date |
December 31, 2020 |
Study information
| Verified date |
May 2021 |
| Source |
St. Erik Eye Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Glaucoma is a complex and chronic eye disease which damages the optic nerve. One of the main
risk factors for the progression of glaucoma is IOP.
The aim of the study is to examine if Salovum, an anti-secretory factor (AF), can reduce the
level of the intraocular pressure (IOP) in the eye of patients affected by glaucoma.
Anti-secretory factor (AF) is an endogenous protein which controls the transport of water and
ions across the cell membrane. AF plays an important part in the immune system and has an
anti-secretory and anti-inflammatory effect.
The investigators' hypothesis is that Salovum can restore a normal salt-water balance in the
eye, which in turn would lower the IOP. This would eliminate or reduce the risk of subsequent
visual impairments/neurological damage.
Description:
The aim of the study is to examine if Salovum, an anti-secretory factor (AF), can reduce the
level of the intraocular pressure (IOP) in the eye of patients affected by glaucoma.
Glaucoma is a complex and chronic eye disease which damages the optic nerve. Beginning at the
periphery of the vision field, it often progresses very slowly, which means that the patients
consult a doctor only when damages have become very large. Glaucoma requires a lifelong
medical treatment. Regardless of the medical treatment, damaged nerve fibers will never
regenerate. An early onset of the medical treatment is crucial to avoid the progression of
the disease which, if not treated, would also affect the central vision, resulting in
patients with severe handicap.
One of the main risk factors for glaucoma is elevated IOP and treatment is aimed to reduce
its progression by IOP lowering. About 10-15 % of glaucoma patients following a medically
correct treatment respond poorly or not at all to the medicines, leading to a progressive
loss of the visual field and an increasingly defective eyesight.
Anti-secretory factor (AF) is an endogenous protein which has been characterized in vivo and
in vitro. AF is a part of the proteasome and controls the transport of water and ions across
the cell membrane. AF plays an important part in the immune system and has an anti-secretory
and anti - inflammatory effect in vivo along with complementary substances, primarily c3C.
Researchers have chemically characterized and cloned AF's cDNA and shown that the active part
(anti-secretory and anti-inflammatory) is located in the amino terminal portion of the
protein. The exact mechanisms behind AF's regulatory effect on the secretory / inflammatory
progress, however, is largely unknown, but AF is probably involved in the liquid transport
mechanisms in the cell pathway.
AF has been detected in most of the body tissues, plasma, breast milk, bile and faeces. In
healthy individual, AF occurs principally in an inactive form, but AF can be activated by a
disease, e.g. the toxin-induced diarrhea. The transition from inactive to active AF
contributes to the normalization of the intestinal secretion and diarrhea decreases or
ceases. In human beings, AF therapy has reduced disease symptoms such as ulcerative colitis,
Crohn's disease, Meniere's disease, mastitis (inflammation of the mammary gland ) and during
diarrhea conditions of different genesis. AF treatment has been particularly successful in
the treatment of children's diarrhea and is routinely used in Pakistan. No side effects of
therapy have so far been reported. Experiences in rats have also shown that AF is effective
in lowering the pressure in the tissue tumors (breast cancer), lowering the elevated
intracranial pressure that arises in connection with virus-induced inflammation of the brain
(herpesvirus type 1), reducing the pressure caused by mechanical brain damage that mimic
stroke (frost damage).
By giving egg-producing hens special feed, hens' own production of AF is stimulated. The high
content of AF is specifically reflected in the egg yolk with a level about 10,000 times
higher than in normal eggs. The AF enriched egg yolk is subjected to spray-drying and sealed
in bags containing 4 gr each. This product is named Salovum and has been registered as a food
for specific medical purposes through the regulatory authorities in the EU. However, Salovum
cannot be used in patients with diagnosed or suspected with egg allergy.
The investigators' hypothesis is that Salovum can restore a normal salt-water balance in the
eye, which in turn would lower the IOP. This would eliminate or reduce the risk of subsequent
visual impairments/neurological damage. It is in this context important to point out that the
intake of Salovum counts as food and does not in any way interfere with the conventional
medical management of glaucoma.
Fifty glaucoma patients who despite adequate medication need additional IOP lowering will be
recruited. Participants will be randomly divided into 2 groups with 25 patients each and will
be treated according to the following:
- one group begins with Salovum during 2 weeks and then take a placebo for another 2 weeks
- one group begins with placebo for 2 weeks and then takes Salovum 2 weeks.
Dosage: Salovum is dissolved in juice or water and may give rise to a certain satiety. Each
bag contains 4 gr of dried egg yolk. The first 2 days, the patients will take one bag of
Salovum or placebo 6 times a day , then a bag 5 times daily for 3 days and finally a bag 4
times daily for 9 days.
The eye which has the highest IOP will be selected. If both eyes have the same IOP, the right
eye will be chosen. IOP will be measured according to Goldmann applanation tonometry five
times during the study period. IOP will be measured three times per session and all three
measurements will be used for statistical analysis. IOP will also be measured with a
self-tonometer by the patients themselves 5 times daily.
Patients will get more detailed information about handling the self-tonometer from study
staff. All results will be stored at St Erik Eye Hospital in a computer system with limited
access.
During the study, patients will continue to take their glaucoma treatment as usual. Except
for drinking Salovum and measuring their IOP, no new routine will encounter.
As the study will compare placebo (egg yolk with a low level of AF) with active treatment
(Salovum with a high dose of AF) within a sick patient population, no healthy subjects will
be included in the study.
If an IOP lowering effect is achieved with Salovum, the investigators will discuss with the
patient how treatment should be continued. If no effect is obtained, patients will continue
with their usual medical treatment only.
